Actively Recruiting
ADELANTE: A Randomized Controlled Trial to Improve Engagement in Care for Latinos With HIV
Led by Massachusetts General Hospital · Updated on 2026-01-09
250
Participants Needed
2
Research Sites
N/A
Total Duration
On this page
Sponsors
M
Massachusetts General Hospital
Lead Sponsor
B
Baylor College of Medicine
Collaborating Sponsor
AI-Summary
What this Trial Is About
This research aims to evaluate the effectiveness of ADELANTE, a behavioral intervention, in helping Latino adults with HIV who have not achieved viral suppression. The study will compare ADELANTE with an enhanced care condition (ECC) to see which better supports viral suppression and reduces emergency room visits and hospitalizations over 12 months. It focuses on participants who have been on HIV treatment for at least three months but still have detectable viral loads. Participants will be randomly assigned to either the ADELANTE group, which receives five individualized problem-solving sessions delivered by bilingual community health workers over six months, or the ECC group, which receives five reminder phone calls without additional intervention. The ADELANTE program uses motivational interviewing, a drama-based HIV telenovela, and links participants to needed services to improve treatment adherence and self-management. Participants will be assessed at the start, then at 3, 6, and 12 months after randomization. These assessments will measure viral suppression, emergency department visits, hospitalizations, and retention in care. Study staff who do not know participants' group assignments will conduct evaluations. Participants will be compensated for each completed assessment, and their progress will be monitored throughout the yearlong study.
CONDITIONS
Brief Title
ADELANTE: A Randomized Controlled Trial to Improve Engagement in Care for Latinos With HIV
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Self-identify as Latino, Latina, Latinx, or Hispanic
- Adults aged 18 years and older
- Confirmed HIV infection by standard laboratory results
- At least 3 months since starting HIV treatment with a provider who can prescribe antiretroviral therapy
- Receiving HIV primary care at specified clinics
- Last viral load showing HIV RNA 200 copies per milliliter or higher within 12 months prior to eligibility assessment
You will not qualify if you...
- Lacks capacity to consent as measured by a validated screener
- Plans to move out of the county within the next 6 months
- Currently participating in another HIV intervention study with ongoing follow-up
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 6 months
Participants receive either 5 individualized problem-solving sessions delivered by a community health worker over 6 months or 5 locator phone calls as part of enhanced care.
5 sessions or phone calls over 6 months
Duration - 12 months post randomization
Participants complete assessments at baseline, month 3, month 6, and month 12 to monitor viral suppression and healthcare engagement.
4 assessment visits
Trial Site Locations
Total: 2 locations
1
University of Miami
Miami, Florida, United States, 33146
Actively Recruiting
2
Baylor College of Medicine
Houston, Texas, United States, 77030
Actively Recruiting
Research Team
J
Julie H Levison, MD
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
HEALTH_SERVICES_RESEARCH
Number of Arms
2
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here